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In Vivo Dosimetry and Seed Localization in Prostate
Brachytherapy With Permanent Implants
Anatoly B. Rosenfeld, Senior Member, IEEE, D. L. Cutajar, M. L. F. Lerch, Member, IEEE, G. J. Takacs, J. Brady,
T. Braddock, V. L. Perevertaylo, Member, IEEE, J. Bucci, J. Kearsley, M. Zaider, and M. Zelefsky
Abstract—This paper reports on the development of an in-
teractive, intraoperative dose planning system for seed implant
brachytherapy in cancer treatment. This system involves in vivo
dosimetry and the ability to determine implanted seed positions.
The first stage of this project is the development of a urethral
alarm probe to measure the dose along the urethra during a
prostate brachytherapy treatment procedure. Ultimately, the
system will be used to advise the physicians upon reaching a preset
dose rate or dose after total seed decay in the urethra during the
seed placement. The second stage is the development of a method
and instrumentation for in vivo measurements of the location of
implanted seeds in the same frame as for dose planning and the use
of these in intraoperative treatment planning. We have developed
a silicon mini-detector, miniature front-end, and shaping ampli-
fier with discriminator, connected to the mini-silicon detector at
the end of a cable placed in a urological catheter, to satisfy the
spectroscopic requirements of the urethral probe. This technique
will avoid complications related to overdosing the urethra and the
rectum.
I. INTRODUCTION
REAL-TIME transrectal ultrasound guided transperinealplacement of permanent interstitial and sources
isoneof the treatmentmodalitiesavailableforearlystageprostate
cancer. There has been a rapid expansion of the use of this pro-
cedure, which is set to become the most common treatment
modality for early stage prostate cancer. Equivalent biochem-
ical control rates for low-risk prostate cancer with permanent
seed implantation in comparison to radical prostatectomy or
external beam radiotherapy have been confirmed [1], [2]. These
biochemical outcomes have been favorable, but there has been
little emphasis on the evaluation and comparison of side effects
and complications. Interstitial brachytherapy exhibits a different
side effect profile than radical prostatectomy or external beam
radiotherapy. Specifically, acute urinary side effects predominate
in interstitial prostate brachytherapy [3]–[5]. Urinary symptoms,
resulting in an increase of the International Prostate Symptom
Score (IPSS), are well-recognized side effects of interstitial
prostate brachytherapy; however, more detailed evaluation of
these symptoms has been lacking. Wallner et al. [6] observed an
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increase in grade-3 late urethral toxicity when the urethral dose
exceeded 400 Gy. Recent recommendations by the American
Brachytherapy Society (ABS) for reporting morbidity after
prostate brachytherapy request urethral doses be recorded for
correlation with urethral toxicity [7]. The ABS recommends that
doses be obtained at the center of the urethra, in half-centimeter
intervals, from the base to the apex of the prostate, reporting the
maximum and mean obtained doses [7].
Medical complications associated with interstitial prostate
brachytherapy can result from errors in seed placement during
insertion. There are several factors that may lead to the mis-
placement of seeds. The guiding needles may diverge during
insertion as different layers of tissue are penetrated [8], resulting
in the incorrect deposition of seeds; the seeds may drift along
the path of the needles; blood flow may alter the seed positions;
oedema may alter the size and shape of the prostate; and gland
motion may occur [9]. There is a need for seed locations to be
monitored in real-time during insertion (intraoperatively). If a
seed is misplaced, the required locations of other seeds may
be recalculated in compensation. Intraoperative localization of
inserted seeds will also provide a method of online dosimetry.
Many difficulties have been encountered in the development
of an interactive planning system in the operating theatre
in prostate brachytherapy [10]. Current commercial systems
use ultrasound visualization of individual seeds or needles to
predict the dose within the prostate during treatment. These
systems are expensive, have problems with artifacts as on
two-dimensional ultrasound seed imaging and are unable to
determine precisely the individual seed locations during a
treatment procedure. The Memorial Sloan-Kettering Cancer
Center (MSKCC) has developed an intraoperative conformal
optimization and planning system (I-3D) for ultrasound-based
transperineal prostate implants [11]. Optimal operation of this
system requires accurate and reproducible real-time position
coordinates of each successively implanted seed. The MSKCC
has also recently developed an intraoperative dosimetry system
for prostate brachytherapy based on the combination of two
imaging techniques [12]. Ultrasound images are obtained of the
prostate and lead markers, which are attached to the ultrasound
probe. Fluoroscopic images of the implanted seeds and lead
markers are also obtained. The seed locations obtained from
the fluoroscopic images are superimposed onto the prostate
images using computer reconstruction. The entire process takes
approximately 10 min [12].
Brachytherapy seeds contain radioactive sources, usually
or . These radioactive sources emit low-energy photons
with a distinct energy spectrum, at very low-dose rates that are
0018-9499/04$20.00 © 2004 IEEE
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TABLE I
6711 SEED PHOTON EMISSION [15]
hard to measure with conventional detectors in confined spaces.
The complexity of the dosimetry of and seeds is due to
the low-doserates, anisotropyofdoseabout theseeds, andrapidly
diminishing dose with distance from the seeds. Traditional in
vivo dosimetry demands miniature, high sensitive and tissue
equivalent dosimeters. Miniature on-line radiotherapy dosime-
ters currently available such as mosfets or diodes are energy
dependent in this spectral range and are not sensitive enough.
Here, we propose the development of an alternative intraoper-
ative dosimetry system based on in vivo spectroscopy. The spec-
troscopymethodofdosimetrydoesnot require tissueequivalency
of the detector and is very sensitive. Spectroscopic dosimetry is
based on separate photopeak analysis rather than the integral ef-
fect of all the photons as in the diode or mosfet dosimeter. Mea-
surements of a particular low-energy X-ray photopeak of known
energy can be used for dosimetry or distance measurements be-
tween a source and a detector. This can be achieved with a minia-
ture X-ray Si detector operating in spectroscopy mode.
At low energies, approximately 27 keV for , most en-
ergy loss occurs through the photoelectric effect. The Compton
scattering cross section is significant, but energy loss due to the
Compton effect is minimal. In this case, the intensity of the pho-
topeak at a distance r from the point source can be represented
as , where is the attenuation coefficient for photons at
a distinct energy penetrating a constant medium. Spectral peaks
of different energies will be attenuated by different amounts as
the emitted photons penetrate the tissue. Using the above prin-
ciple, the ratio of peak heights or area under the peaks in an ob-
tained spectrum will yield the distance from a point source to the
detector. In the case of multiple seed implants (i.e., permanent
seed implants) where each seed is implanted sequentially, the in-
crease in the rate of change of area or peak height from one seed
implant to the next will be used to deduce the newly implanted
seed position. If the distance to one detector is known, the trian-
gulation of distances from a noncoplanar array of detectors will
yield the seed position. The ability of solid-state detectors to
resolve the low-energy photons, such as those in Table I, is im-
proving as new detector technologies are being developed. Such
a system will be intraoperative and will allow online dosimetry
of the treatment.
II. MATERIALS AND METHODS
Monte Carlo simulations and experimental measurements
were performed on an OncoSeed number 6711 from Amersham
Health [13]. This seed consists of radioactive , adsorbed
onto a silver rod, encapsulated in a hollow titanium cylinder
with welded ends. The geometry of the seed was obtained from
Williamson [14]. The silver rod is 3 mm in length and 0.5 mm
in diameter. A 1- m-thick coating of silver halide is present
on the rod. The radioactive iodine was assumed to be at the
midpoint of the silver halide coating. The titanium shell was
4.5 mm in length, 0.8 mm in diameter, 0.06-mm thick along
the sides, and 0.5-mm thick at the end welds. decays via
electron capture, emitting photons of several distinct energies
through gamma and X-ray emission. Internal conversion and
Auger electrons are also emitted, but were neglected, as they
would not penetrate the titanium shell. A 3.6-keV photon was
also neglected.
Due to the presence of silver in the seed, silver fluorescent
X-rays of energies 22.1 and 25.2 keV [16] are present.
Monte Carlo simulations were performed using EGSnrcV2
[17]. The FLURZnrc user code was used to simulate the 6711
seed in a liquid water phantom. The energy spectrum was ob-
tained at various locations for distances up to 5 cm from the
seed center at various angles around the seed. The real energy
resolution of any detector used to measure these spectra was not
taken into account during simulation. This resulted in the energy
peaks being very sharp, occupying only one or two channels per
peak in each energy spectrum. The area under each photon peak
was calculated for each obtained spectrum. This equated to the
total number of counts in the one or two channels occupied by
each photopeak. The ratios of peak areas were calculated for
the 27-, 31-, and 35-keV peak. These obtained peak ratios were
plotted versus distance from the seed and angle about the seed
axis. An algorithm relating peak ratio to seed location was then
constructed.
Given that we have a method for determining the distance
from a seed to a detector, and we have four or more noncoplanar
detectors, we can determine the location of the seed. For ex-
ample, if we have “n” detectors, each at a known location ,
and the distance from each detector determined from analysis
of the spectrum is , then we may determine the seed location
from minimization of the following function:
(1)
The location , which minimizes this, is then the estimate of
the seed location.
III. RESULTS
From Fig. 1, it can be seen that the photon peaks in the en-
ergy spectrum of the 6711 seed are very sharp, with very little
scattering, even after the photons have traversed 5 cm of liquid
water. This allows the use of spectroscopy for analysis of the ra-
diation throughout the prostate during interstitial brachytherapy.
The areas under the 27-, 31-, and 35-keV peaks were calculated
for each obtained spectra. Figs. 2 and 3 are plots of the ratio
of the area under two separate peaks versus distance along the
transverse axis of the seed.
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Fig. 1. FLURZnrc energy spectrum of a 6711 seed, measured 5 cm from seed
along the transverse axis. After traversing 5 cm of water, the energy peaks are
still very sharp, with minimal low-energy tails.
Fig. 2. Ratio of the area under the 27-keV peak to the area under the 35-keV
peak versus distance along the transverse axis for the 6711 seed, obtained from
the FLURZnrc spectra.
Since scattering is minimal and the majority of energy loss
occurs through the photoelectric effect, the area under each peak
as a function of distance may be given by
(2)
where is the area under a single peak, is the area at zero
distance, is the attenuation coefficient of the medium for pho-
tons of the peak energy, and is the distance from the seed to the
point of measurement. The ratio of the area under two peaks,
and , may be given by
(3)
where is the ratio of the area under peak to the area under
peak , is the peak ratio at zero distance, and is the
Fig. 3. Ratio of the area under the 31-keV peak to the area under the 35-keV
peak versus distance along the transverse axis for the 6711 seed, obtained from
the FLURZnrc spectra.
Fig. 4. Ratio of the area under the 27-keV peak to the area under the 35-keV
peak versus distance for a 6711 seed in a water phantom, calculated at various
angles around the seed. An angle of 90 represents measurements along the
transverse axis of the seed.
difference in attenuation coefficients . Using (3) and
the data obtained from the FLURZnrc simulations of the 6711
seed in water, the following equations were devised
(4)
(5)
The distance to a 6711 seed within liquid water may be deter-
mined by calculating the ratio of the area underneath two peaks
in the spectrum and using (4) or (5). This assumes the point of
measurement is along the transverse axis of the seed.
The previous calculations were repeated for spectra obtained
at different angles around a 6711 seed in a liquid water phantom.
A plot of versus distance was obtained in Fig. 4.
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Fig. 5. Normalized plot of R versus the angle to determine the function
g() . Ratios were calculated 1 cm from the seed center for different angles.
Fig. 6. Normalized plot of R versus the angle to determine the function
g() . Ratios were calculated 1 cm from the seed center for different angles.
It can be seen from Fig. 4 that the peak ratios vary with
changes in source angle. This is due to the variation in thickness
of the titanium shell around the seed. Photons at lower angles
traverse a greater thickness of titanium, increasing the attenua-
tion, lowering the peak ratios. Simply finding the ratio of any
two peaks in a measured spectrum is not enough to determine
the distance to the seed. The peak ratios are a function of both
distance and angle. Assuming the distance from the seed to the
detector is much larger than the thickness of the titanium jacket
surrounding the source within the seed, the peak ratios may be
represented as separable functions of both distance and angle
(6)
where is the distance dependent function of the peak ratio
and g is the angular dependent function of the peak ratio.
was previously found to be . To determine the an-
gular dependent function of the peak ratios g , the peak ratios
versus angle were plotted for a distance of 1 cm, normalized,
and shown in Figs. 5 and 6.
Fig. 7. Normalized plot of R versus the angle to determine the function
g() , for various distances from the seed center.
After taking into account the angular variance in peak ratios,
(4) and (5) become
(7)
(8)
By calculating the area under the 27-, 31-, and 35-keV peaks for
an obtained spectrum, performing ratios of the obtained areas and
solving (7) and (8) simultaneously, the distance to the seed aswell
as the angle of the seed to the point of measurement may be deter-
mined. Fig. 7 shows the normalized plot of versus angle
for various distances up to 5 cm from the seed. The curves show a
similar trend, with small discrepancies at low angles. These dis-
crepancies are due to an increase in statistical error as the thicker
titanium shell at the end welds of the seed greatly attenuates the
photons, reducing the counts at low angles.
In order to determine the practicality of this approach for
determining seed positions, we have conducted simulations
where seeds are placed at random in a specified cubical treat-
ment volume. The cubical volume has variable dimensions
in order to see the effects of different prostate volumes on
the feasibility of the method. Four detectors are placed in a
tetrahedral configuration within the cubical treatment volume.
The tetrahedral detector arrangement and the cubical treatment
volume share a common center. A seed is placed at a randomly
selected location in the treatment volume, as shown in Fig. 8.
The distance between each detector and the seed is calculated
from the known coordinates. In practice, the distance that the
seed is from a given detector will be determined by a signal
from the detector. This will differ from the actual distance due
to the effects of noise and uncertainties due to seed anisotropy.
In order to simulate the effect of this uncertainty, each distance
is varied randomly to introduce errors. These errors are uniform
distributions in the range of 2% and 5%. The uncertain dis-
tances are then used, along with the known detector positions
, in (1). The seed location, , which minimizes this expres-
sion, is then deduced using the downhill simplex method [18],
and compared to the actual seed location. The distance between
the deduced and actual seed location is recorded as the error
for that seed location. This procedure is then repeated a large
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Fig. 8. Cubical treatment volume containing a centralized tetrahedral detector
configuration and a brachytherapy seed at a randomly generated location within
the treatment volume.
TABLE II
ERRORS IN SEED LOCATION
number of times in order to get a reasonable idea of the range
of errors for each configuration. The results of this process are
summarized in Table II for various combinations of treatment
volume size, tetrahedral detector configuration size, and for two
different precisions in seed-detector distances.
The first column of Table II specifies the size of the cubical
treatment volume. The tetrahedron dimensions are given in the
second column. In the third column, we note the assumed uncer-
tainty in the distance between the seed and detector. The average
error, in the fourth column, refers to the average, over one mil-
lion seed placements, of the difference in the seed position as
returned by the function minimization and the known seed po-
sition. The final column lists the percentage of seeds for which
an error of greater than 2.5 mm occurred.
The results of Table II show that the proportion of times a
large seed location error occurs is sensitive to the precision with
which the seed-detector distances can be determined. An in-
crease in this error by a factor of 2.5 results in an increase
by the same factor in the average error, but the proportion of
times an error of greater than 2.5 mm occurs increases by a
much greater factor. For a fixed experimental precision in deter-
mining seed-detector distances, the average error is proportional
to the cube edge length of the treatment volume, or the treatment
volume to the one-third power. Thus, if such a method should
prove feasible, it should work better for smaller treatment vol-
umes.
Fig. 9. The 6711 seed spectrum, measured with the urethra alarm probe
connected to the preamplifier via a 40-cm cable. The 27-keV peak is well
resolved. The 31 and 35-keV peaks are well resolved, but do not contain many
counts. Also present is the 22-keV silver X-ray peak. The 27-keV peak is
outlined and has a FWHM of 2.3 keV.
The described technique for seed localization measurements,
in the case of permanent implants in a prostate, demands the
placement of a minimum of four noncoplanar detectors. These
mini-detectors will be placed in needles and will be introduced
into the prostate prior to seed implantation. The detectors should
be small enough to be inserted into a 1-mm diameter needle,
and must be operated in spectroscopy mode with energy resolu-
tion suitable for the resolving of X-ray peaks from or
seeds. An important issue is the efficiency of the detector, which
should be enough to provide good statistics within a short time
(1–3 s) after each seed has been implanted, while, on the other
hand, pulse pile up should be avoided. When multiple seeds
are present, each additional seed changes the rate of increase
of counts in each channel. This increment in the count rate pro-
vides the spectral information, which is analyzed to determine
the distance from each detector to the latest seed.
Currently, we have developed an in vivo dosimetry system for
the urethra, the urethra alarm probe, as a first stage of the project.
This uses spectroscopy to estimate the dose to the urethra during
interstitial brachytherapy treatment. The probe consists of a sil-
icon mini-detector of dimensions 0.8 0.8 3 mm. This is con-
nected to a preamplifier/amplifier system by a thin 40-cm cable,
allowing the placement of the detector within the prostate via a
urinary catheter. The described probe was used to measure the
energy spectrum of a 6711 seed in air at 25 C, while connected
to the amplifier system via a 40-cm cable that would be used in
practice. The resulting spectrum is shown in Fig. 9.
The 6711 seed spectrum in Fig. 9 demonstrates that the cur-
rent detector system is able to resolve the peaks necessary for
use in the seed localization procedure. Analysis of the ratio of
the peak amplitudes measured in air does not correspond to the
frequencies in Table I, as emitted by an source, or the ra-
tios shown in Figs. 2 and 3. This is due to the efficiency of the
silicon detector varying with incident photon energy. This ef-
ficiency needs to be taken into account in the proposed tech-
nique for seed location measurements. The photon spectrum of
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the 6711 seed was also measured with the photons incident on
the rear of the detector. There was no apparent change in the
measured spectrum, indicating that the detector was fully de-
pleted and has an isotropic response to photon irradiation.
IV. CONCLUSION
The the development of an intraoperative treatment planning
system for low-dose rate brachytherapy of the prostate, based
on in vivo spectroscopic dosimetry, has many advantages. The
most important advantage is the allowance for seed localization,
measured in real time. It was demonstrated that small Si detec-
tors are a good choice for a spectroscopic localization system.
Such a system will allow for updating of the treatment plan to
correct for seed misplacement, and online dosimetry. A method
exists for locating seeds, based on distances between each of
four detectors and a seed, with each of these distances being de-
termined by observation of the ratio of counts under different
energy peaks. This method will need to be expanded for use in
prostate brachytherapy where the seed count is large and seeds
may be implanted too far from a detector to give an adequate
response increment. To approach this, we propose the use of an
array of at least 16 detectors, implanted on several needles. A
data acquisition system will then be used to monitor the incre-
ment in counts from all detectors and choose the best combina-
tion of four noncoplanar detectors to be used for the localization
algorithm. The determination of the distance from a seed to a
detector is possible, theoretically, and is currently under inves-
tigation in a tissue equivalent phantom. The recently developed
urethra alarm probe, based on a silicon mini-detector operating
in spectroscopy mode, is the first stage of the project, and is suit-
able for real time dosimetry within the urethra, without the need
for a tissue equivalent dosimeter.
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